01
Cash & equivalents decreased 53.6%
Cash & equivalents changed -53.6% from the comparable as-filed period.
$117.1M→$54.3MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTTrevi Therapeutics, Inc.'s latest supported as-filed period reports interest income of $935,000. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -53.6% from the comparable as-filed period.
Net income changed -44.7% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating income changed -49.5% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
TRVI · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-338023SEC ↗8-KAug 6, 2026Period Aug 6, 20260001193125-26-337974SEC ↗4Jun 4, 2026Period Jun 3, 20260001193125-26-257488SEC ↗8-KJun 4, 2026Period Jun 3, 20260001193125-26-257365SEC ↗4Jun 4, 2026Period Jun 3, 20260001193125-26-257370SEC ↗4Jun 4, 2026Period Jun 3, 20260001193125-26-257373SEC ↗4Jun 4, 2026Period Jun 3, 20260001193125-26-257371SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 3, 2026Filed Jun 4, 2026 | Mathers Edward TDirector | Grant Or AwardDirect | 35,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +61.4% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Stock-based compensation changed +136.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-257366